ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 Pathways

Wang, Gang; Ma, Chao; Chen, Kai; Wang, Ziyi; Qiu, Heng; Chen, Delong; He, Jianbo; Zhang, Cheng; Guo, Ding; Lai, Boyong; Zhang, Shuangxiao; Huang, Linfeng; Yang, Fan; Yuan, Jinbo; Chen, Leilei*; He, Wei*; Xu, Jiake*广州中医药大学; 1; jk
Frontiers in Pharmacology2022-1-20DOI: 10.3389/fphar.2021.810322
13被引11阅读
引用收藏
分享

摘要

Osteoporosis, which typically affects postmenopausal women, is an osteolytic disease due to over-activation of osteoclasts. However, current drugs targeting osteoclast inhibition face various side effects, making natural compounds with great interest as alternative treatment options. Cycloastragenol (CAG) is a triterpenoid with multiple biological activities. Previously, CAG's activity against aging-related osteoporosis was reported, but the mechanisms of actions for the activities were not understood. This study demonstrated that CAG dose-dependently inhibited osteoclast formation in receptor activator of nuclear factor-kappa B ligand (RANKL)-stimulated bone marrow macrophage (BMMs). Mechanism studies showed that CAG inhibited NF-kappa B, calcium, and nuclear factor of activated T cells 1 (NFATc1) pathways. Additionally, CAG also promoted the nuclear factor-erythroid 2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1)/anti-oxidative response element (ARE) pathway that scavenges reactive oxygen species (ROS). Furthermore, CAG was also found to prevent bone loss of postmenopausal osteoporosis (PMO) in a preclinical model of ovariectomized (OVX) mice. Collectively, our research confirms that CAG inhibits the formation and function of osteoclasts by regulating RANKL-induced intracellular signaling pathways, which may represent a promising alternative for the therapy of osteoclast-related disease.

学科与关键词

关键词
cycloastragenolosteoclastRANKLNfatc1ROS
相关
加载中…
  • Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca2+-NFATc1 and Cav-1 signaling pathways
    Zou, Binhua; Zheng, Jiehuang; Deng, Wende; Tan, Yanhui; Jie, Ligang; Qu, Yuan; Yang, Qin; Ke, Minhong; Ding, Zongbao; Chen, Yan; Yu, Qinghong*; Li, Xiaojuan*PHYTOMEDICINE, 2021, 80: 153377.被引 20
  • Asiatic Acid Inhibits OVX-Induced Osteoporosis and Osteoclastogenesis Via Regulating RANKL-Mediated NF-κb and Nfatc1 Signaling Pathways
    Hong, Guoju; Zhou, Lin; Han, Xiaorui; Sun, Ping; Chen, Zhenqiu; He, Wei; Tickner, Jennifer; Chen, Leilei*; Shi, Xuguang*; Xu, Jiake*Frontiers in Pharmacology, 2020, 11: 331.被引 19
  • A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species
    Hong, Guoju; Chen, Zhenqiu; Han, Xiaorui; Zhou, Lin; Pang, Fengxiang; Wu, Rishana; Shen, Yingshan; He, Xiaoming; Hong, Zhinan; Li, Ziqi; He, Wei; Wei, Qiushi*Clinical and Translational Medicine, 2021, 11(5): e392.被引 31
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-01-20
卷期
第 12 卷
页码
810322
DOI
10.3389/fphar.2021.810322
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Australian National Health and Medical Research Council [APP1163933]; National Natural Science Foundation of China [81873327]; Science and Technology Planning Project of Guangdong Province [2017B090912007]; Visiting Program for Graduate Students from Guangzhou University of Chinese Medicine (GZUCM) [(2017)74]; Discipline collaborative innovation team project of double first-class and high-level university of GZUCM [2021XK05]

作者

  • W

    Wang, Gang (第一作者)

    1 · guangzhou univ chinese med

  • M

    Ma, Chao

    guangzhou univ chinese med

查看全部 17 位作者收起作者
  • C

    Chen, Kai

  • W

    Wang, Ziyi

  • Q

    Qiu, Heng

  • C

    Chen, Delong

    guangzhou univ chinese med

  • H

    He, Jianbo

    guangzhou univ chinese med

  • Z

    Zhang, Cheng

    guangzhou univ chinese med

  • G

    Guo, Ding

    guangzhou univ chinese med

  • L

    Lai, Boyong

    guangzhou univ chinese med

  • Z

    Zhang, Shuangxiao

    guangzhou univ chinese med

  • H

    Huang, Linfeng

    guangzhou univ chinese med

  • Y

    Yang, Fan

    guangzhou univ chinese med

  • Y

    Yuan, Jinbo

  • C

    Chen, Leilei (通讯)

    guangzhou univ chinese med

  • H

    He, Wei (通讯)

    guangzhou univ chinese med

  • X

    Xu, Jiake (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417